{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rigouts L"],"funding":["University of Antwerp","European Research Council","Damien Foundation Belgium","Dehousse","European Research Council Starting"],"pagination":["314-23"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4710215"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["71(2)"],"pubmed_abstract":["<h4>Objectives</h4>Mutations in the gyrase genes cause fluoroquinolone resistance in Mycobacterium tuberculosis. However, the predictive value of these markers for clinical outcomes in patients with MDR-TB is unknown to date. The objective of this study was to determine molecular markers and breakpoints predicting second-line treatment outcomes in M. tuberculosis patients treated with fourth-generation fluoroquinolones.<h4>Methods</h4>We analysed treatment outcome data in relation to the gyrA and gyrB sequences and MICs of ofloxacin, gatifloxacin and moxifloxacin for pretreatment M. tuberculosis isolates from 181 MDR-TB patients in Bangladesh whose isolates were susceptible to injectable drugs.<h4>Results</h4>The gyrA 90Val, 94Gly and 94Ala mutations were most frequent, with the highest re"],"journal":["The Journal of antimicrobial chemotherapy"],"pubmed_title":["Specific gyrA gene mutations predict poor treatment outcome in MDR-TB."],"pmcid":["PMC4710215"],"funding_grant_id":["311725"],"pubmed_authors":["Hossain MA","Fissette K","Rieder HL","Coeck N","Rigouts L","Van Deun A","Aung KJ","de Rijk WB","Meehan CJ","Gumusboga M","de Jong BC"],"additional_accession":[]},"is_claimable":false,"name":"Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.","description":"<h4>Objectives</h4>Mutations in the gyrase genes cause fluoroquinolone resistance in Mycobacterium tuberculosis. However, the predictive value of these markers for clinical outcomes in patients with MDR-TB is unknown to date. The objective of this study was to determine molecular markers and breakpoints predicting second-line treatment outcomes in M. tuberculosis patients treated with fourth-generation fluoroquinolones.<h4>Methods</h4>We analysed treatment outcome data in relation to the gyrA and gyrB sequences and MICs of ofloxacin, gatifloxacin and moxifloxacin for pretreatment M. tuberculosis isolates from 181 MDR-TB patients in Bangladesh whose isolates were susceptible to injectable drugs.<h4>Results</h4>The gyrA 90Val, 94Gly and 94Ala mutations were most frequent, with the highest re","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Feb","modification":"2025-04-19T01:55:15.486Z","creation":"2019-03-27T02:06:45Z"},"accession":"S-EPMC4710215","cross_references":{"pubmed":["26604243"],"doi":["10.1093/jac/dkv360"]}}